BackgroundClinicians lack substantiated guidance on when vitamin K antagonist (VKA) treatment should be interrupted preoperatively, especially with regard to phenprocoumon, with its long half‐life of 5.5 days.ObjectiveTo evaluate the efficacy of discontinuing phenprocoumon 5 days preoperatively and determine whether a safe international normalized ratio (INR) was reached.MethodsThis was a retrospective review of 118 patients using phenprocoumon prior to elective surgery. Preoperative INRs and factors that could potentially influence these values were identified and described. A safe preoperative INR was defined as <1.8.ResultsOf the 118 included patients, 42 patients (35.6%) had an off‐target INR. The male sex was significantly and independently associated with an off‐target INR (odds ratio [OR] 2.4, 95% confidence interval [CI] 1.022‐5.445). A high American Society of Anesthesiologists (ASA) classification was also significantly and independently associated with an off‐target INR (OR 2.3, 95% CI: 1.029‐5.173).ConclusionDiscontinuation of phenprocoumon 5 days preoperatively resulted in an INR < 1.8 in more than one‐third of patients. Individualizing or extending the period of phenprocoumon discontinuation may be a necessary treatment option.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.